4.6 Article

Clinical management of cannabis withdrawal

Journal

ADDICTION
Volume 117, Issue 7, Pages 2075-2095

Publisher

WILEY
DOI: 10.1111/add.15743

Keywords

assessment; cannabis withdrawal syndrome; clinical management; pharmacology; prevalence; time course

Funding

  1. Australian Government
  2. CAMH, a clinician-scientist award from the department of Family and Community Medicine of the University of Toronto
  3. Chair in Addiction Psychiatry from the department of Psychiatry of University of Toronto
  4. US National Institute on Drug Abuse (NIDA) [P30DA029926, T32DA037202, R01DA015186]

Ask authors/readers for more resources

This review examines the diagnosis, prevalence, course, and management of cannabis withdrawal. The onset of symptoms typically occurs within 24-48 hours after cessation and peak between days 2-6. The most common symptoms include anxiety, irritability, disturbed sleep, depressed mood, and loss of appetite. Currently, there are no approved medications for medically assisted withdrawal, but some promising pharmacological agents have been explored in controlled trials.
Background and Aims Cannabis withdrawal is a well-characterized phenomenon that occurs in approximately half of regular and dependent cannabis users after abrupt cessation or significant reductions in cannabis products that contain Delta(9)-tetrahydrocannabinol (THC). This review describes the diagnosis, prevalence, course and management of cannabis withdrawal and highlights opportunities for future clinical research. Methods Narrative review of literature. Results Symptom onset typically occurs 24-48 hours after cessation and most symptoms generally peak at days 2-6, with some symptoms lasting up to 3 weeks or more in heavy cannabis users. The most common features of cannabis withdrawal are anxiety, irritability, anger or aggression, disturbed sleep/dreaming, depressed mood and loss of appetite. Less common physical symptoms include chills, headaches, physical tension, sweating and stomach pain. Despite limited empirical evidence, supportive counselling and psychoeducation are the first-line approaches in the management of cannabis withdrawal. There are no medications currently approved specifically for medically assisted withdrawal (MAW). Medications have been used to manage short-term symptoms (e.g. anxiety, sleep, nausea). A number of promising pharmacological agents have been examined in controlled trials, but these have been underpowered and positive findings not reliably replicated. Some (e.g. cannabis agonists) are used 'off-label' in clinical practice. Inpatient admission for MAW may be clinically indicated for patients who have significant comorbid mental health disorders and polysubstance use to avoid severe complications. Conclusions The clinical significance of cannabis withdrawal is that its symptoms may precipitate relapse to cannabis use. Complicated withdrawal may occur in people with concurrent mental health and polysubstance use.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available